SCHEMBL23342178

SCHEMBL23342178

CC(C)C(=O)N1CCC2(CCN(C(C)C)C2=O)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.36
RIPK1 Q13546 1/20 0.35
ACACB O00763 2/20 0.34
ACACA Q13085 2/20 0.34
CCR1 P32246 2/20 0.32
NOTUM Q6P988 1/20 0.31
AOC2 O75106 1/20 0.31
USP30 Q70CQ3 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
CHRNB3 Q05901 1/20 0.31
CHRNA6 Q15825 1/20 0.31
USP19 O94966 2/20 0.31
DDB1 Q16531 1/20 0.31
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30
PIK3R1 P27986 2/20 0.30
PIK3CA P42336 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23342004 0.93 ACACB (0.38) CRBNRIPK1ACACBACACAAOC2
SCHEMBL23338590 0.92 ACACB (0.33) CRBNRIPK1ACACBACACANOTUM
SCHEMBL23342007 0.90 AOC2 (0.34) RIPK1ACACBACACAAOC2CHRNB2
SCHEMBL23342003 0.83 ACACB (0.34) ACACBACACANOTUMCHRNB2CHRNA3
SCHEMBL25919798 0.82 OPRM1 (0.43) CRBNRIPK1ACACBACACAAOC2
SCHEMBL25919762 0.80 NOTUM (0.31) CRBNNOTUMCHRNB2CHRNA3CHRNA4
SCHEMBL25912482 0.77 ALDH1A1 (0.41) CRBNACACBACACAAOC2CHRNB2
SCHEMBL24338396 0.76 GRIN2B (0.45) CRBNACACBACACA
SCHEMBL17118711 0.76 CYP3A4 (0.38) CRBNDDB1PIK3CD
SCHEMBL22156260 0.75 CHRM2 (0.38) ACACBACACAAOC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20210130326-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS CRBN 461/4885RIPK1 1490/4885ACACB 3313/4885
US-20210130326-A1 RAS INHIBITORS KRAS, NRAS, HRAS CRBN 377/4885RIPK1 819/4885ACACB 3273/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR CRBN 308/4885RIPK1 826/4885ACACB 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.